Nurix TherapeuticsInc Ownership

NRIX
 Stock
  

USD 11.71  0.47  3.86%   

Some institutional investors establish a significant position in stocks such as Nurix TherapeuticsInc in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Nurix TherapeuticsInc, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Additionally, see Correlation Analysis.
  
Nurix TherapeuticsInc holds a total of 47.15 Million outstanding shares. The majority of Nurix TherapeuticsInc outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nurix TherapeuticsInc to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nurix TherapeuticsInc. Please pay attention to any change in the institutional holdings of Nurix TherapeuticsInc as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Nurix Stock Ownership Analysis

About 94.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.56. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nurix TherapeuticsInc recorded a loss per share of 3.05. The entity had not issued any dividends in recent years. Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company was incorporated in 2009 and is headquartered in San Francisco, California. Nurix Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people. To find out more about Nurix TherapeuticsInc contact the company at 415 660 5320 or learn more at https://www.nurixtx.com.

Nurix TherapeuticsInc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nurix TherapeuticsInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nurix TherapeuticsInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nurix TherapeuticsInc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Van Houte Hans over a month ago via Macroaxis 
Exercise or conversion by Van Houte Hans of 2886 shares of Nurix Therapeutics subject to Rule 16b-3
Saltzman Edward C over two months ago via Macroaxis 
Acquisition by Saltzman Edward C of 50000 shares of Nurix Therapeutics subject to Rule 16b-3
Van Houte Hans over three months ago via Macroaxis 
Acquisition by Van Houte Hans of 120000 shares of Nurix Therapeutics subject to Rule 16b-3
Van Houte Hans over three months ago via Macroaxis 
Exercise or conversion by Van Houte Hans of 2886 shares of Nurix Therapeutics subject to Rule 16b-3
Van Houte Hans over six months ago via Macroaxis 
Exercise or conversion by Van Houte Hans of 68333 shares of Nurix Therapeutics subject to Rule 16b-3
Lacey David L over six months ago via Macroaxis 
Acquisition by Lacey David L of 17500 shares of Nurix Therapeutics subject to Rule 16b-3
Van Houte Hans over six months ago via Macroaxis 
Exercise or conversion by Van Houte Hans of 2886 shares of Nurix Therapeutics subject to Rule 16b-3
Van Houte Hans over six months ago via Macroaxis 
Acquisition by Van Houte Hans of 46177 shares of Nurix Therapeutics subject to Rule 16b-3
Ring Christine over six months ago via Macroaxis 
Exercise or conversion by Ring Christine of 1200 shares of Nurix Therapeutics subject to Rule 16b-3
Hansen Gwenn over six months ago via Macroaxis 
Exercise or conversion by Hansen Gwenn of 1428 shares of Nurix Therapeutics subject to Rule 16b-3
Ring Christine over six months ago via Macroaxis 
Exercise or conversion by Ring Christine of 1200 shares of Nurix Therapeutics subject to Rule 16b-3
Hansen Gwenn over six months ago via Macroaxis 
Exercise or conversion by Hansen Gwenn of 400 shares of Nurix Therapeutics subject to Rule 16b-3

Be your own money manager

Our tools can tell you how much better you can do entering a position in Nurix TherapeuticsInc without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Nurix TherapeuticsInc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Correlation Analysis. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for analysis

When running Nurix TherapeuticsInc price analysis, check to measure Nurix TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix TherapeuticsInc is operating at the current time. Most of Nurix TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Nurix TherapeuticsInc's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nurix TherapeuticsInc's price. Additionally, you may evaluate how the addition of Nurix TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Is Nurix TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nurix TherapeuticsInc. If investors know Nurix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nurix TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
584.2 M
Quarterly Revenue Growth YOY
0.053
Return On Assets
(0.23) 
Return On Equity
(0.48) 
The market value of Nurix TherapeuticsInc is measured differently than its book value, which is the value of Nurix that is recorded on the company's balance sheet. Investors also form their own opinion of Nurix TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Nurix TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nurix TherapeuticsInc's market value can be influenced by many factors that don't directly affect Nurix TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nurix TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine Nurix TherapeuticsInc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nurix TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.